Ascelia Pharma AB (OSTO:ACE) Cash And Cash Equivalents : kr57.30 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Ascelia Pharma AB Cash And Cash Equivalents?

Ascelia Pharma AB's quarterly cash and cash equivalents declined from Sep. 2024 (kr95.72 Mil) to Dec. 2024 (kr75.26 Mil) but then stayed the same from Dec. 2024 (kr75.26 Mil) to Mar. 2025 (kr57.30 Mil).

Ascelia Pharma AB's annual cash and cash equivalents declined from Dec. 2022 (kr149.56 Mil) to Dec. 2023 (kr21.86 Mil) but then increased from Dec. 2023 (kr21.86 Mil) to Dec. 2024 (kr75.26 Mil).

Ascelia Pharma AB Cash And Cash Equivalents Historical Data

The historical data trend for Ascelia Pharma AB's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascelia Pharma AB Cash And Cash Equivalents Chart

Ascelia Pharma AB Annual Data

Trend

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

184.69

261.60

149.56

21.86

75.26

Ascelia Pharma AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															26.54	29.78	95.72	75.26	57.30

Ascelia Pharma AB Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Ascelia Pharma AB (OSTO:ACE) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Ascelia Pharma AB Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Ascelia Pharma AB's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascelia Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (OSTO:ACE) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

7ZA:Germany

Address

Hyllie Boulevard 34, Malmo, SWE, 215 32

Website

https://www.ascelia.com

Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.

Ascelia Pharma AB Headlines

No Headlines